Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

PHARMACIE DE LA ROUGE PORTE : revenue, balance sheet and financial ratios

PHARMACIE DE LA ROUGE PORTE is a French company founded 17 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in HALLUIN (59250), this company of category PME shows in 2017 a revenue of 1.6 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-04-25

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - PHARMACIE DE LA ROUGE PORTE (SIREN 507668283)
Indicator 2024 2023 2022 2021 2020 2019 2018 2017
Revenue N/C N/C N/C N/C N/C N/C N/C 1 552 542 €
Net income 68 951 € 166 953 € 38 010 € 44 277 € 68 895 € 102 475 € 106 984 € 108 697 €
EBITDA N/C N/C N/C N/C N/C N/C N/C 123 226 €
Net margin N/C N/C N/C N/C N/C N/C N/C 7.0%

Revenue and income statement

In 2024, PHARMACIE DE LA ROUGE PORTE generates positive net income of 69 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2024: 109 k€ -> 69 k€.

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

68 951 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 332%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 21%. The balance between equity and debt is satisfactory.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

331.568%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

21.362%

Asset age ratio (2024) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

72.8%

Solvency indicators evolution
PHARMACIE DE LA ROUGE PORTE

Sector positioning

Debt ratio
331.57 2024
2022
2023
2024
Q1: 16.46
Med: 58.48
Q3: 154.77
Average +50 pts over 3 years

In 2024, the debt ratio of PHARMACIE DE LA ROUGE PORTE (331.57) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
21.36% 2024
2022
2023
2024
Q1: 28.91%
Med: 49.95%
Q3: 69.47%
Watch -51 pts over 3 years

In 2024, the financial autonomy of PHARMACIE DE LA ROUGE PORTE (21.4%) ranks in the bottom 25% of the sector. This ratio represents the share of equity in total financing. Low autonomy may limit investment capacity and increase vulnerability.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 165.98. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

165.977

Liquidity indicators evolution
PHARMACIE DE LA ROUGE PORTE

Sector positioning

Liquidity ratio
165.98 2024
2022
2023
2024
Q1: 129.46
Med: 182.14
Q3: 260.79
Average +21 pts over 3 years

In 2024, the liquidity ratio of PHARMACIE DE LA ROUGE PORTE (165.98) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
PHARMACIE DE LA ROUGE PORTE

Positioning of PHARMACIE DE LA ROUGE PORTE in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 225 transactions of similar company sales in 2024, the value of PHARMACIE DE LA ROUGE PORTE is estimated at 962 606 € (range 670 344€ - 1 440 115€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2024
225 transactions
670k€ 962k€ 1440k€
962 606 € Range: 670 344€ - 1 440 115€
NAF 5 année 2024

Valuation method used

Net Income Multiple
68 951 € × 14.0x = 962 607 €
Range: 670 344€ - 1 440 115€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare PHARMACIE DE LA ROUGE PORTE with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about PHARMACIE DE LA ROUGE PORTE

What is the revenue of PHARMACIE DE LA ROUGE PORTE ?

The revenue of PHARMACIE DE LA ROUGE PORTE in 2017 is 1.6 M€.

Is PHARMACIE DE LA ROUGE PORTE profitable?

Yes, PHARMACIE DE LA ROUGE PORTE generated a net profit of 69 k€ in 2024.

Where is the headquarters of PHARMACIE DE LA ROUGE PORTE ?

The headquarters of PHARMACIE DE LA ROUGE PORTE is located in HALLUIN (59250), in the department Nord.

Where to find the tax return of PHARMACIE DE LA ROUGE PORTE ?

The tax return of PHARMACIE DE LA ROUGE PORTE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does PHARMACIE DE LA ROUGE PORTE operate?

PHARMACIE DE LA ROUGE PORTE operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.